CN116554319A - Preparation and application of anti-human integrase interaction molecule 1 (INI 1) rabbit monoclonal antibody - Google Patents
Preparation and application of anti-human integrase interaction molecule 1 (INI 1) rabbit monoclonal antibody Download PDFInfo
- Publication number
- CN116554319A CN116554319A CN202210611547.XA CN202210611547A CN116554319A CN 116554319 A CN116554319 A CN 116554319A CN 202210611547 A CN202210611547 A CN 202210611547A CN 116554319 A CN116554319 A CN 116554319A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- ini
- rabbit monoclonal
- ini1
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 102100026389 PHD finger-like domain-containing protein 5A Human genes 0.000 title claims abstract description 9
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 title abstract description 6
- 102100034343 Integrase Human genes 0.000 title abstract description 5
- 108010061833 Integrases Proteins 0.000 title abstract description 5
- 230000003993 interaction Effects 0.000 title abstract description 5
- 101000835860 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Proteins 0.000 claims abstract description 34
- 102100025746 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Human genes 0.000 claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims abstract description 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 6
- 238000011587 new zealand white rabbit Methods 0.000 claims abstract description 5
- 229920001184 polypeptide Polymers 0.000 claims abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 5
- 238000010369 molecular cloning Methods 0.000 claims abstract description 3
- 238000012360 testing method Methods 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 210000001519 tissue Anatomy 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 108010078791 Carrier Proteins Proteins 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 210000002741 palatine tonsil Anatomy 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 208000013076 thyroid tumor Diseases 0.000 claims description 3
- 201000000170 Thyroid lymphoma Diseases 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 238000002372 labelling Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 238000013115 immunohistochemical detection Methods 0.000 abstract description 3
- 230000006798 recombination Effects 0.000 abstract description 3
- 238000005215 recombination Methods 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000001514 detection method Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002649 immunization Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000002570 interstitial cell Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 102000052049 SMARCB1 Human genes 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000007538 neurilemmoma Diseases 0.000 description 3
- 206010039667 schwannoma Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000008938 Rhabdoid tumor Diseases 0.000 description 2
- 108700028341 SMARCB1 Proteins 0.000 description 2
- 101150008214 SMARCB1 gene Proteins 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 102000047678 human SMARCB1 Human genes 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- PKOHVHWNGUHYRE-ZFWWWQNUSA-N (2s)-1-[2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)NCC(=O)N1CCC[C@H]1C(O)=O PKOHVHWNGUHYRE-ZFWWWQNUSA-N 0.000 description 1
- UGLPMYSCWHTZQU-AUTRQRHGSA-N Ala-Ala-Tyr Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 UGLPMYSCWHTZQU-AUTRQRHGSA-N 0.000 description 1
- QDGMZAOSMNGBLP-MRFFXTKBSA-N Ala-Trp-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N QDGMZAOSMNGBLP-MRFFXTKBSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- DXQIQUIQYAGRCC-CIUDSAMLSA-N Arg-Asp-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)CN=C(N)N DXQIQUIQYAGRCC-CIUDSAMLSA-N 0.000 description 1
- PRLPSDIHSRITSF-UNQGMJICSA-N Arg-Phe-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PRLPSDIHSRITSF-UNQGMJICSA-N 0.000 description 1
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 1
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 1
- QHAJMRDEWNAIBQ-FXQIFTODSA-N Asp-Arg-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O QHAJMRDEWNAIBQ-FXQIFTODSA-N 0.000 description 1
- VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 description 1
- SFJUYBCDQBAYAJ-YDHLFZDLSA-N Asp-Val-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SFJUYBCDQBAYAJ-YDHLFZDLSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- HHABWQIFXZPZCK-ACZMJKKPSA-N Cys-Gln-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N HHABWQIFXZPZCK-ACZMJKKPSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- SHERTACNJPYHAR-ACZMJKKPSA-N Gln-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O SHERTACNJPYHAR-ACZMJKKPSA-N 0.000 description 1
- FJAYYNIXQNERSO-ACZMJKKPSA-N Gln-Cys-Asp Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N FJAYYNIXQNERSO-ACZMJKKPSA-N 0.000 description 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 1
- IHSGESFHTMFHRB-GUBZILKMSA-N Gln-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(N)=O IHSGESFHTMFHRB-GUBZILKMSA-N 0.000 description 1
- OTQSTOXRUBVWAP-NRPADANISA-N Gln-Ser-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OTQSTOXRUBVWAP-NRPADANISA-N 0.000 description 1
- ZQFAGNFSIZZYBA-AAEUAGOBSA-N Gln-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(N)=O)N)C(O)=O)=CNC2=C1 ZQFAGNFSIZZYBA-AAEUAGOBSA-N 0.000 description 1
- VAIWPXWHWAPYDF-FXQIFTODSA-N Glu-Asp-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O VAIWPXWHWAPYDF-FXQIFTODSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- JHSRJMUJOGLIHK-GUBZILKMSA-N Glu-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N JHSRJMUJOGLIHK-GUBZILKMSA-N 0.000 description 1
- WXONSNSSBYQGNN-AVGNSLFASA-N Glu-Ser-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WXONSNSSBYQGNN-AVGNSLFASA-N 0.000 description 1
- HJTSRYLPAYGEEC-SIUGBPQLSA-N Glu-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCC(=O)O)N HJTSRYLPAYGEEC-SIUGBPQLSA-N 0.000 description 1
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 1
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
- ZLFNNVATRMCAKN-ZKWXMUAHSA-N Ile-Ser-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZLFNNVATRMCAKN-ZKWXMUAHSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- FKQPWMZLIIATBA-AJNGGQMLSA-N Leu-Lys-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FKQPWMZLIIATBA-AJNGGQMLSA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 1
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 1
- GAHJXEMYXKLZRQ-AJNGGQMLSA-N Lys-Lys-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GAHJXEMYXKLZRQ-AJNGGQMLSA-N 0.000 description 1
- XLTSAUGGDYRFLS-UMPQAUOISA-N Met-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCSC)N)O XLTSAUGGDYRFLS-UMPQAUOISA-N 0.000 description 1
- 208000009287 Myoepithelioma Diseases 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 1
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 1
- QUBVFEANYYWBTM-VEVYYDQMSA-N Pro-Thr-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O QUBVFEANYYWBTM-VEVYYDQMSA-N 0.000 description 1
- VVAWNPIOYXAMAL-KJEVXHAQSA-N Pro-Thr-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VVAWNPIOYXAMAL-KJEVXHAQSA-N 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 101710199691 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- QGMLKFGTGXWAHF-IHRRRGAJSA-N Ser-Arg-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QGMLKFGTGXWAHF-IHRRRGAJSA-N 0.000 description 1
- VAIZFHMTBFYJIA-ACZMJKKPSA-N Ser-Asp-Gln Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O VAIZFHMTBFYJIA-ACZMJKKPSA-N 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 1
- OSFZCEQJLWCIBG-BZSNNMDCSA-N Ser-Tyr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSFZCEQJLWCIBG-BZSNNMDCSA-N 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- LMMDEZPNUTZJAY-GCJQMDKQSA-N Thr-Asp-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O LMMDEZPNUTZJAY-GCJQMDKQSA-N 0.000 description 1
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
- XXNLGZRRSKPSGF-HTUGSXCWSA-N Thr-Gln-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O XXNLGZRRSKPSGF-HTUGSXCWSA-N 0.000 description 1
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 1
- KBLYJPQSNGTDIU-LOKLDPHHSA-N Thr-Glu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O KBLYJPQSNGTDIU-LOKLDPHHSA-N 0.000 description 1
- BNGDYRRHRGOPHX-IFFSRLJSSA-N Thr-Glu-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O BNGDYRRHRGOPHX-IFFSRLJSSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- LXXCHJKHJYRMIY-FQPOAREZSA-N Thr-Tyr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O LXXCHJKHJYRMIY-FQPOAREZSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HYVLNORXQGKONN-NUTKFTJISA-N Trp-Ala-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 HYVLNORXQGKONN-NUTKFTJISA-N 0.000 description 1
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 1
- YLRLHDFMMWDYTK-KKUMJFAQSA-N Tyr-Cys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLRLHDFMMWDYTK-KKUMJFAQSA-N 0.000 description 1
- AKLNEFNQWLHIGY-QWRGUYRKSA-N Tyr-Gly-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N)O AKLNEFNQWLHIGY-QWRGUYRKSA-N 0.000 description 1
- UPODKYBYUBTWSV-BZSNNMDCSA-N Tyr-Phe-Cys Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CS)C(O)=O)C1=CC=C(O)C=C1 UPODKYBYUBTWSV-BZSNNMDCSA-N 0.000 description 1
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- MIAZWUMFUURQNP-YDHLFZDLSA-N Val-Tyr-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N MIAZWUMFUURQNP-YDHLFZDLSA-N 0.000 description 1
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of biology, and discloses a rabbit anti-human integrase interaction molecule 1 (INI 1) rabbit monoclonal antibody OTIR4G9, and the amino acid sequences of an antibody light chain variable region (VL) and a heavy chain variable region (VH) are shown as SEQ ID NO.4 and SEQ ID NO. 5. The inventor also provides a preparation method of the anti-INI 1 rabbit monoclonal antibody, and the antibody is produced by screening specific B cells through molecular cloning recombination after the INI1 polypeptide is utilized to immunize New Zealand white rabbits. The anti-INI 1 rabbit monoclonal antibody can be used in an immunodetection tool for detecting INI1 protein, and comprises an immunohistochemical detection kit, other labeled tissue cell kits, test paper and the like. The monoclonal antibody has higher specificity and sensitivity, can be specifically combined with INI1 protein, and obviously improves the specificity and reliability of INI1 protein immunodetection.
Description
Technical Field
The invention relates to the field of biotechnology, in particular to a method and application for detecting immunity by specifically combining an anti-integrase interaction molecule 1 (INI 1) rabbit monoclonal antibody with the integrase interaction molecule 1.
Background
The INI-1 gene, located at 22q11.2, also known as hSNF 5, SMARCB1 and BAF47, is a core subunit of the SWI/S NF complex and plays a role in the remodeling of ATP dependent chromatin, thereby regulating gene expression and is associated with a variety of cellular functions, including repair of damaged DNA and regulation of cell growth. In 1998, it was first clarified that the deletion expression of INI1 protein due to the inactivation of both alleles of INI1 was a characteristic change of MRT in malignant rhabdoid tumor using gene localization method. SMARCA4 (BRG 1), S MARCA2 (BRM) and SMARCB1 (INI 1) belong to members of the chromatin remodeling complex family, and these gene mutations or deletions lead to gene inactivation, which is manifested by loss of expression of the corresponding protein by immunohistochemical detection. These protein expression deletions may occur singly or in several accompaniments in different tumors. The tumor cells are often characterized by striated muscle-like cells in histology, which are often found in highly malignant tumors with strong aggressiveness and poor prognosis. The loss of INI1 expression is most commonly seen in malignant rhabdoid tumors, epithelioid sarcomas. Second, partial epithelial-like malignant peripheral schwannoma, malignant pigment schwannoma, epithelioid schwannoma, low differentiation chordoma, and few extraosseous mucoid chondrosarcoma and soft tissue myoepithelial tumors all seen a loss of INI1 expression.
Recent studies indicate that the expression pattern of INI1 varies among tumors. Abnormal expression of INI1 proteins can be divided into three modes: complete loss, mosaic expression and reduced expression. When the protein INI1 is completely lost, the expression of the protein INI1 in tumor cells is negative, and cells such as interstitial cells, vascular endothelial cells and the like serving as internal controls are positive. Currently, INI1 monoclonal antibodies are commonly used for diagnosing malignant rhabdomyomas and related diseases in pathological diagnosis.
The immunohistochemical pathology is established on the protein level, so that the tissue source, the primary part, the pathological typing, the residual marginal cancer cells and the like of the tumor can be further judged, and the diagnosis effect and the prognosis guiding effect are realized; the core immunohistochemical pathology needs to have an antibody with strong specificity and high sensitivity, especially a monoclonal antibody. With the intensive research into diseases and INI1 proteins, the application range of anti-INI 1 monoclonal antibodies is continuously extended. Meanwhile, with the popularization of automatic instruments, the difference of detection conditions of various large detection platforms and the rapid development of pathological AI, the requirements on quality of the antibody are higher and higher. However, the development of high-quality anti-INI 1 monoclonal antibodies with strong specificity and high sensitivity suitable for different detection platforms is urgent due to the lack of high-quality anti-INI 1 monoclonal antibodies.
Disclosure of Invention
The invention aims to provide a rabbit monoclonal antibody specifically binding to INI1 protein and application thereof in preparing an immunodetection tool for detecting INI1 protein.
The invention provides an anti-INI 1 rabbit monoclonal antibody which is OTIR4G9, wherein an antibody light chain variable region (VL) of the rabbit monoclonal antibody contains 108 amino acids, and the sequence of the rabbit monoclonal antibody is shown as SEQ ID NO. 4; the heavy chain variable region (VH) contains 116 amino acid sequences as shown in SEQ ID NO. 5.
The rabbit monoclonal antibody specifically recognizes the INI1 protein.
The inventor provides a preparation method of the antibody, synthesizes 3-segment polypeptides and respectively couples the 3-segment polypeptides to carrier protein KLH to serve as immunogens for immunization of New Zealand white rabbits. After obtaining Peripheral Blood Mononuclear Cells (PBMCs) of immunized animals, sorting specific B cells, carrying out molecular cloning and transfection of recombinant vectors into mammalian cells, culturing the cells to obtain supernatant containing secreted antibodies, and carrying out affinity hierarchical purification on the supernatant to obtain the anti-INI 1 rabbit monoclonal antibodies.
The invention also provides application of the anti-INI 1 rabbit monoclonal antibody in preparation of an immunodetection tool for detecting INI1 protein. The immunodetection tool comprises a kit, a chip or test paper and the like.
The invention also provides an immunohistochemical detection kit which comprises an anti-INI 1 rabbit monoclonal antibody and can detect the expression condition of INI1 protein in tissue cells. Such tissues include, but are not limited to, normal tissues: tonsils, thyroid glands, spleen and stomach; tumor tissue: lung cancer, breast cancer, thyroid tumor, lymphoma and INI 1-deficient expressed tumor tissue.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below.
FIG. 1 IHC results on normal tissue of the anti-INI 1 rabbit monoclonal antibody OTIR4G9.
FIG. 2 IHC results of the anti-INI 1 rabbit monoclonal antibody OTIR4G9 on INI1 positive tumor tissue.
FIG. 3 IHC results of the anti-INI 1 rabbit monoclonal antibody OTIR4G9 on INI1 deleted expression tumor tissue.
Detailed Description
The invention discloses a preparation method of an anti-INI 1 rabbit monoclonal antibody, a method for immunodetection and application thereof. The technical solutions in the embodiments of the present invention will be clearly and completely described below in connection with the embodiments of the present invention. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. Based on the examples of the present invention, one skilled in the art can, given the benefit of this disclosure, suitably modify the implementation of the process parameters. It is expressly pointed out that all other embodiments which can be obtained by the person concerned without making any inventive effort fall within the scope of protection of the present invention.
Example 1: preparation of anti-INI 1 rabbit monoclonal antibodies
1. Preparation of antigens
The INI1 protein sequence NP-003064.2 was obtained on the NCBI website and contained 385 amino acids as standard sequences. Amino acid sequences 114-131, 246-262, 357-379 were selected for synthesis and coupled to the carrier protein KLH, respectively, as immunogens.
2. Immunization of animals
The above synthesized INI1 polypeptide was synthesized according to 1:1:1, and immunizing about 2kg of New Zealand white rabbits by a subcutaneous injection method, wherein the immune dose is 500 mug/animal, and the immune dose is 250 mug/animal after two weeks of interval for a second immunization. Tail blood is taken after three times of immunization, and serum titer is measured by ELISA and IHC method gradient dilution; based on the ELISA titers 128000 with an OD450 of greater than 1.0 and the intensity of the nuclear stain signal detected on the tissue by IHC, it was determined whether PBMCs were collected or continued immunization.
PBMCs isolation, specific B cell sorting and cloning recombination
Fixing the immunized New Zealand white rabbits with standard serum detection titer on an operating table, shaving the furs of heart parts, wiping and sterilizing skin by alcohol cotton balls, selecting the most obvious heart beat part, puncturing by a 50ml syringe, flushing blood into the syringe after a needle penetrates into the heart, rapidly pulling out the needle after the required blood volume is obtained, transferring whole blood in the syringe into a sterile 50ml tube, uniformly mixing with equal amount of PBS, slowly adding dropwise above lymphocyte separation liquid, centrifuging at room temperature of 400 Xg for 30min, and dividing the liquid level into four layers from top to bottom: yellow plasma layer, white thin film layer (i.e. mononuclear cell layer), separated liquid layer and erythrocyte layer. The rabbit PBMCs were obtained by carefully pipetting the mononuclear cell layer and washing with PBS to remove platelet and lymphocyte isolates. Antigen-specific B cells were sorted therefrom and cultured, and positive clones were screened with antigen-coated ELISA plates. Positive clones are lysed, lysate is collected, RNA is extracted from the positive clones, the RNA is reversely transcribed into cDNA, the full-length sequence of the light and heavy chains of the naturally paired rabbit monoclonal antibodies is amplified from the cDNA of the corresponding positive clone, a rabbit monoclonal antibody expression vector is constructed by a cloning recombination method, and the sequence is determined by sequencing.
4. Preparation and purification of monoclonal antibodies
In order to obtain a rabbit monoclonal antibody capable of specifically recognizing human INI1 protein, the invention loads a heavy chain and a light chain gene of the rabbit monoclonal antibody onto an expression vector, and transfects a recombinant plasmid into HEK293 cells; the supernatant was incubated 120-144h after transfection with recombinant rabbit monoclonal antibodies recognizing human INI1 protein. Collecting cell suspension, centrifuging to obtain supernatant, and performing antibody purification by affinity chromatography. The concentration of the purified monoclonal antibody was measured by BCA method.
EXAMPLE 2 analysis of the variable region Gene and amino acid sequence of the rabbit monoclonal antibody OTIR4G9
And respectively taking recombinant plasmids of the OTIR4G9 antibody as DNA templates, designing a light chain variable region and a heavy chain variable region sequencing primer according to the 5' -end carrier sequences of the light chain and the heavy chain on the templates, and sequencing by adopting a sequencer ABI 3730. The nucleotide sequence of the rabbit monoclonal antibody OTIR4G9 light chain variable region is obtained by sequencing. And (3) carrying out sequencing result data analysis on the nucleotide sequences of the light chain and the heavy chain by using IMGT/V-QUEST analysis software on http:// www.imgt.org to obtain the light chain amino acid sequence of the rabbit monoclonal antibody OTIR4G9, wherein the light chain amino acid sequence is shown as SEQ ID NO.4, and the heavy chain amino acid sequence is shown as SEQ ID NO. 5. The total length of the light chain variable region (VL) is 108 amino acids, the number of amino acids of the 4 domains of FR is 26, 17, 36 and 10, the number of amino acids of the 3 domains of CDR is 8, 3 and 8, the regions of CDR1, CDR2 and CDR3 are 27aa-34aa,52aa-54aa and 91aa-98aa, respectively, the amino acid sequences of which are: QSVYNND; QAS; LGGYDDDV. The heavy chain variable region (VH) contains 116 amino acids and the number of amino acids in the 4 domains of its FR is 24, 17, 36 and 11, respectively; the amino acid numbers of 3 domains of the CDR are 8, 7 and 13 respectively, the corresponding amino acid regions are 25-32aa, 50-56aa and 93-105aa respectively, and the sequence is GFSLSSYY; SSSSGST; ARVEDDDYGDTYA.
Example 3: IHC detection of rabbit monoclonal antibody OTIR4G9
1. Experimental method
(1) Paraffin embedding was performed on formalin-fixed tissue blocks, and sections were performed using a Leica tissue microtome, with a tissue thickness of 4 μm.
(2) Dewaxing and hydration: analytical grade xylene 10min×3 times, absolute ethanol 10min×3 times, 95% ethanol 5min,85% ethanol 5min,75% ethanol 5min, deionized water 3min×3 times.
(3) Adding antigen retrieval liquid [1mM EDTA,10mM Tris buffer (pH8.0) ] into autoclave for 2.5min, opening the autoclave when the temperature of the autoclave is reduced to about 90 ℃, taking out the specimen, and naturally cooling to room temperature. The deionized water is soaked for 3min multiplied by 3 times.
(4) Tissue endogenous peroxidase was inactivated with 3% hydrogen peroxide, and left to stand at room temperature for 10min. The deionized water is soaked for 5min multiplied by 3 times.
(5) anti-INI rabbit monoclonal antibody OTIR4G9 (0.51. Mu.g/ml) was added and placed in a wet box and incubated at 37℃for 60min. Wash 5min×3 times with PBST (0.1% Tween-20).
(6) A supersensitive enzyme-labeled goat anti-mouse/rabbit IgG polymer (Catalog No. PV-8000) was added dropwise and incubated at 37℃for 30min. Wash 5min x 3 times with PBS.
(7) The color development was performed using DAB solution for 5min. Washing with distilled water.
(8) Hematoxylin counterstains the nuclei for 2min, rinsing with distilled water, and differentiating with 1% hydrochloric acid. Rinsing with distilled water for 3 times, and standing at room temperature for 1min.
(9) Dehydration and transparency: 75% ethanol 5min,85% ethanol 5min,95% ethanol 5min,100% ethanol 3X 5min; xylene 3×5min, neutral resin seals.
(10) And (5) microscopic examination.
2. Experimental results:
normal tissues, INI1 expression and tumor tissues with deletion expression were examined by IHC method using anti-INI 1 rabbit monoclonal antibody otor 4G9 as primary antibody, with the following results:
(1) IHC results on the tonsils, thyroid, spleen and stomach of normal tissues are shown in FIG. 1, which shows that in these 4 tissues, various cells have different degrees of nuclear staining, i.e., INI1 expression is seen in different cell types of different tissues. Consistent with literature reports.
(2) The results of the staining on the lung cancer, breast cancer, lymphoma and thyroid tumor positive for INI1 are shown in FIG. 2, and the results show that the INI1 is expressed in both tumor cells and interstitial cells, the positive signals on the tumor cells are stronger than those on the interstitial cells in the same sample, and the cells with active proliferation have stronger expression and are consistent with the functions of the INI 1.
(3) The staining results in tumor tissues with INI1 deletion expression are shown in FIG. 3, the left image is the result under a low power microscope, the right image is the enlarged image in the box of the left image, the results show that tumor cells are uncolored, negative, and the arrow indicates that the nuclei of vascular endothelial cells as an internal control are positive.
In conclusion, the rabbit monoclonal antibody OTIR4G9 of the anti-INI 1 protein, which is independently developed, shows nuclear positivity in various normal tissues and tumor tissues through IHC detection, shows negativity on tumor cells which partially lack and express the tumor tissues, and shows positivity on vascular endothelial and interstitial cells which serve as internal control, so that the anti-INI 1 protein monoclonal antibody OTIR4G9 has good specificity, and shows good staining effect when the antibody concentration is only 0.51 mug/ml, so that the clone has higher sensitivity, and can completely meet the requirements of pathologists on the anti-INI 1 monoclonal antibody.
Sequence listing
<110> tin-free Aodi Ruidong Biotechnology Co., ltd
<120> preparation of anti-human integrase interacting molecule 1 (INI 1) rabbit monoclonal antibody and use thereof
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 18
<212> PRT
<213> Homo sapiens
<400> 1
Thr Glu Pro Pro Thr Tyr Leu Arg Glu Gln Lys Ala Lys Arg Asn Ser
1 5 10 15
Gln Trp
<210> 2
<211> 17
<212> PRT
<213> Homo sapiens
<400> 2
Glu Ser Tyr Pro Thr Asp Ser Ile Leu Glu Asp Gln Ser Asp Gln Arg
1 5 10 15
Val
<210> 3
<211> 23
<212> PRT
<213> Homo sapiens
<400> 3
Thr Asp Ala Glu Met Glu Lys Lys Ile Arg Asp Gln Asp Arg Asn Thr
1 5 10 15
Arg Arg Met Arg Arg Leu Ala
20
<210> 4
<211> 108
<212> PRT
<213> Oryctolagus cuniculus
<400> 4
Ala Ala Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly
1 5 10 15
Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Asn Asn
20 25 30
Asn Asp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu
35 40 45
Leu Ile Tyr Gln Ala Ser Arg Leu Ala Ser Gly Val Pro Ser Arg Phe
50 55 60
Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val
65 70 75 80
Gln Cys Asp Asp Ala Ala Ala Tyr Tyr Cys Leu Gly Gly Tyr Asp Asp
85 90 95
Asp Val Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105
<210> 5
<211> 116
<212> PRT
<213> Oryctolagus cuniculus
<400> 5
Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro
1 5 10 15
Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Tyr
20 25 30
Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Gly
35 40 45
Ile Ser Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly
50 55 60
Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr
65 70 75 80
Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Val Glu
85 90 95
Asp Asp Asp Tyr Gly Asp Thr Tyr Ala Trp Gly Pro Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
Claims (8)
1. An anti-INI 1 rabbit monoclonal antibody, characterized in that: the rabbit monoclonal antibody is OTIR4G9.
2. A preparation method of an anti-INI 1 rabbit monoclonal antibody is characterized by comprising the following steps: amino acid sequences 114-131, 246-262 and 357-379 of INI1 protein are respectively coupled to carrier protein KLH to be used as immunogens, and the sequences are shown as SEQ ID NO.1-SEQ ID NO. 3. Mixing the polypeptides in the step 3, injecting to immunize New Zealand white rabbits, obtaining Peripheral Blood Mononuclear Cells (PBMCs) of immunized animals, sorting specific B cells, transfecting the specific B cells into mammalian cells through molecular cloning and recombinant vectors, and purifying the supernatant through an affinity hierarchy.
3. An anti-INI 1 rabbit monoclonal antibody, characterized in that: the antibody light chain variable region (VL) contains 108 amino acids, contains 3 epitopes: CDR1, CDR2 and CDR3, the epitope regions are 27-34aa, 52-54aa, 91-98aa, respectively, and the sequences are shown in SEQ ID NO. 4; the heavy chain variable region (VH) contains 116 amino acids and 3 epitopes: CDR1, CDR2 and CDR3, the epitope regions are 25-32aa, 50-56aa, 93-105aa, respectively, and the sequences are shown in SEQ ID NO. 5.
4. The rabbit monoclonal antibody of claim 2, wherein: the monoclonal antibodies specifically recognize the INI1 protein.
5. According to claim 4, the rabbit monoclonal antibody can be used in an immunoassay kit for detecting INI1 protein.
6. The immunoassay kit according to claim 5, which includes but is not limited to a kit, a chip, a test paper, etc.
7. The rabbit monoclonal antibody according to claim 4, which can be used in a kit for labeling tissue cells and tumor cells.
8. The use of claim 7, the normal tissue comprising: tonsils, thyroid glands, spleen and stomach; tumor tissues include lung cancer, breast cancer, thyroid tumor, lymphoma and tumor tissues with deletion expression of INI 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210611547.XA CN116554319A (en) | 2022-06-01 | 2022-06-01 | Preparation and application of anti-human integrase interaction molecule 1 (INI 1) rabbit monoclonal antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210611547.XA CN116554319A (en) | 2022-06-01 | 2022-06-01 | Preparation and application of anti-human integrase interaction molecule 1 (INI 1) rabbit monoclonal antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116554319A true CN116554319A (en) | 2023-08-08 |
Family
ID=87498823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210611547.XA Pending CN116554319A (en) | 2022-06-01 | 2022-06-01 | Preparation and application of anti-human integrase interaction molecule 1 (INI 1) rabbit monoclonal antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116554319A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118027191A (en) * | 2024-02-20 | 2024-05-14 | 武汉爱博泰克生物科技有限公司 | Monoclonal antibody combined with human chromosome plastic molecule and application thereof |
-
2022
- 2022-06-01 CN CN202210611547.XA patent/CN116554319A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118027191A (en) * | 2024-02-20 | 2024-05-14 | 武汉爱博泰克生物科技有限公司 | Monoclonal antibody combined with human chromosome plastic molecule and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9429577B2 (en) | Anti-uroplakin II antibodies systems and methods | |
| EP2754672B1 (en) | Antibody capable of binding to specific region of periostin, and method of measuring periostin using the same | |
| CN114989303B (en) | anti-CD 56 recombinant rabbit monoclonal antibody and application thereof | |
| CN115073602B (en) | anti-CD 3 recombinant rabbit monoclonal antibody and application thereof | |
| CN114507287A (en) | anti-CLDN 18.2 recombinant rabbit monoclonal antibody and application thereof | |
| CN114516919A (en) | anti-PLA 2R recombinant rabbit monoclonal antibody and application thereof | |
| CN117700543B (en) | anti-MLH 1 recombinant rabbit monoclonal antibody and application thereof | |
| CN116554319A (en) | Preparation and application of anti-human integrase interaction molecule 1 (INI 1) rabbit monoclonal antibody | |
| KR100238559B1 (en) | Monoclonal antibodies to hapatitis c virus | |
| KR101777254B1 (en) | Specific monoclonal antibody from a specific antigen EN2 protein or composition comprising the same for diagnosis of prostate cancer | |
| AU8053291A (en) | Measuring non-dystrophin proteins and diagnosing muscular dystrophy | |
| CN104031149B (en) | The preparation of anti-PML albumen nuclear localization signal antibody and its application in APL diagnosis | |
| CN117659187B (en) | Anti-human NUT protein rabbit monoclonal antibody and application thereof | |
| CN118063605A (en) | Anti-human BRG1 rabbit monoclonal antibody, preparation method and application thereof | |
| CN116554333A (en) | Anti-human mucin 6 (MUC 6) rabbit monoclonal antibodies and uses thereof | |
| EP0908466B1 (en) | Anti-human lect2 antibody, cells producing the same, and method and kit for assaying the same | |
| CN117946263A (en) | Anti-human H3K27me3 protein rabbit monoclonal antibody and application thereof | |
| CN114990074B (en) | Hybridoma cell strain, anti-human fumarate hydratase monoclonal antibody and application thereof | |
| CN118359714B (en) | Anti-MCM 2 mouse monoclonal antibody, preparation method thereof and application of immunohistochemical reagent | |
| CN114507286B (en) | anti-PD-L1 recombinant rabbit monoclonal antibody and application thereof | |
| CN115724966A (en) | Anti-human pairing box gene 2 rabbit monoclonal antibody, preparation method and application thereof | |
| CN117700544B (en) | anti-MSH 2 recombinant rabbit monoclonal antibody and application thereof | |
| CN114874309B (en) | TEX101 recombinant protein and application thereof in preparation of monoclonal antibody | |
| CN117362438B (en) | RELT-resistant recombinant monoclonal antibody, and preparation method and application thereof | |
| CN116425873B (en) | anti-CK 6 recombinant rabbit monoclonal antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |